Disclaimer

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions



DO YOU WISH TO CONTINUE AND ENTER THIS WEBSITE?

SJM-CV WEB-0718-0009

/content/bss/divisionalsites/livesites/reusable/cv-livesite/us/en/pages/home
30
CARDIOVASCULAR
hamburger
BACK
Clinical Evidence

Clinical Evidence

Customized Therapy Delivery for Improved Outcomes

Abbott DeFT Response™ technology allows physicians to customize rescue therapy to each patient’s unique cardiac physiology and changing condition.

  • One of the greatest risks associated with implantable cardioverter defibrillator (ICD) therapy is failing to attain acceptable defibrillation thresholds (DFTs)
  • The growing trend of ICD implants without DFT testing presents another challenge with the lack of confirmation of an adequate safety margin
  • It is difficult to predict which patients will have a compromised safety margin1-3
  • Failure from traditional methods adds risk, time and cost to the hospital by requiring additional hardware2,4
  • By combining the ability to measure a patient’s cell depolarization time with consistent HV Lead Impedance, physicians can tailor therapy to an individual patient’s physiology

Clinical Data to Support DeFT Response Technology

  • DeFT Response technology in Abbott patients resulted in a significantly higher proportion of patients with satisfactory DFTs.5
  • “Tuned” defibrillation waveforms outperform 50/50% tilt defibrillation waveforms.6

DeFT Response Technology Optimizes Shock Performance With or Without A DFT Test5*

DeFT Response technology preserved a 10 J safety margin for 100% of the Abbott patients.

17% of the fixed-tilt group of patients with competitive devices had compromised the 10 J safety margin.

  Group A: Adjustable
Abbott		 Group B: Fixed-tilt
Boston Scientific, Medtronic, Biotronik
  NICM ICM NICM ICM
14J — 20 (59%) — 24 (34%)
21J 7 (20%) 3 (9%) 17 (24%) 8 (11%)
25J 1 (3%) 3 (9%) 7 (10%) 3 (4%)
31J 0 0 6 (8%) 4 (6%)
35J 0 0 2 (3%) 0

Method: Analysis of DFT levels for 105 patients implanted with a single coil lead between Aug 2007 and Aug 2010.

  • Group A: patients with waveform tuning (Abbott)
  • Group B: patients with fixed-tilt waveform (60% Boston Sci., 34% Medtronic, 6% Biotronik)

DFT Testing: VF induced by synchronized T-wave shock or direct current pulse. If initial shock failed, second shock delivered at highest energy within 10 J safety margin of device. If unsuccessful, a subcutaneous coil implanted and DFT test repeated. Note: the RV-coil was specifically programmed as an anode in all devices.

*Applies to single coil systems.

References

  1. Leong-Sit, P., Gula, L. J., Diamantouros, P., Krahn, A. D., Skanes, A. C., Yee, R., & Klein, G. J. (2006). Effect of defibrillation testing on management during implantable cardioverterdefibrillator implantation. American Heart Journal, 152(6), 1104-1108.
  2. Russo, A. M., Sauer, W., Gerstenfeld, E. P., Hsia, H. H., Lin, D., Cooper, J. M., ... Marchlinkski, F. E. (2005). Defibrillation threshold testing: is it really necessary at the time of implantable cardioverter-defibrillator insertion? Heart Rhythm, 2, 456-461.
  3. Shukla, H. H., Flaker, G. C., Jayam, V., & Roberts, D. (2003). High defibrillation thresholds in transvenous biphasic implantable defibrillators: clinical predictors and prognostic implications. PACE, 26(1 Pt 1), 44-48.
  4. Cooper, J., Latacha, M., Soto, G., Garmany, R. G., Gleva, M. J., Chen, J., ... Smith, T. W. (2008). The azygos defibrillator lead for elevated defibrillation thresholds: implant technique, lead stability, and patient series. PACE, 31, 1405-1410.
  5. Gabriels, J., Budzikowski, A., & Kassotis, J. (2013). Defibrillation Waveform Duration Adjustment Increases the Proportion of Acceptable Defibrillation Thresholds in Patients Implanted with Single-Coil Defibrillation Leads. Cardiology, 124(2), 71-75.
  6. Natarajan, S., Henthorn, R., Burroughs, J., Esberg, D., Zweibel, S., Ross, T., ... Oza, A. (2007). “Tuned” Defibrillation Waveforms Outperform 50/50% Tilt Defibrillation Waveforms: A Randomized Multi-Center Study. Pacing Clin Electrophysiol, 1, S139-42.
Indications, Safety & Warnings

MAT-2205144 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

YESNO
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO